Business Wire

INFINITY-VENTURES

29.4.2020 06:16:07 CEST | Business Wire | Press release

Share
Lake House Group Chairman Donates 2.5 Million Masks to European Governments

In response to the impact of COVID-19 on European communities, Lake House Group Chairman Charles Brown has donated and coordinated delivery of 2.5 million masks to three European nations in order to stem the spread of the virus. He said “Masks are a low-cost, effective intervention for stopping the spread of the virus and getting people back to work safely.”

A Hong Kong native with European roots, Brown has donated one million masks each to the Kingdom of Spain and the Federal Republic of Germany, with an additional 500,000 masks designated for Région Sud in France. “The masks landed in Spain and Germany on 15 and 19 April, respectively, and the masks bound for southern France are currently in transit,” reported Torsten Hartmann, Managing Director for Europe in Lake House’s London office.

While traveling in Europe prior to widespread lockdowns, Brown noted with concern that few European citizens wore masks in public. Regarding Hong Kong’s low number of confirmed cases since the outbreak began there on 23 January, Brown stated “The 2003 SARS epidemic taught Hong Kongers to be vigilant about wearing masks, and that experience shows.”

The donation efforts have been spearheaded by Brian Lu, Venture Partner at the Japanese venture capital firm Infinity Ventures, in which Charles Brown is a Limited Partner. The firm’s portfolio company, Hong Kong-based logistics startup Buyandship, has worked to ensure the masks are delivered with as little burden as possible on the governments receiving the donations.

According to Lu, “We’ve seen how tough it’s been for governments to obtain masks from trusted sources and get them delivered efficiently, so we’re proud to be able to help these countries get masks into people’s hands as quickly as possible.”

“Giving money is an easy thing if you have it, but a more effective thing is to deliver the goods to the point where they are needed, and that’s what we’re trying to achieve here,” added Lake House’s Charles Brown. “I hope our efforts are able to spark other private donors to use their resources and connections to make similar efforts,” he said.

About Lake House Group

Established in 1995, Lake House Group is a private investment company founded by Hong Kong native Charles Brown, who is also Chairman Emeritus and Founding Board Member of the United Nations Peace Development Foundation in China. Lake House is led by CEO David Timblick, and invests in businesses across the globe at every stage. With offices in Hong Kong and London, the firm is involved in projects and investments in excess of US$15 billion across 15 countries.

About Infinity Ventures

Infinity Ventures is a venture capital firm, focused on early stage Internet companies, founded in Japan in 2008, with offices in Tokyo, Taipei, and Beijing. The firm manages $255M USD, and has invested in 91 startups and produced 9 IPOs. Since its founding, Infinity Ventures has grown alongside its portfolio companies to build category-leading innovators and unicorns including Groupon, Farfetch, freee, Yeahka, WealthNavi, and 17 Media.

About Buyandship

Buyandship is a cross-border e-commerce logistics company established in 2014. The company provides a one-stop transit service for goods bought in the United States, United Kingdom, Japan, Korea, and China. Buyandship currently maintains warehouses in multiple countries, with daily scheduled flights to Hong Kong and other markets in Asia.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 09:30:00 CET | Press release

First preclinical data on the Company’s lead program MOS101: a combination of ASTX295, a next-generation, clinical-stage MDM2 antagonist, and olaparib, an FDA-approved PARP inhibitor, in biomarker-selected solid tumorsAdditional data showcasing Mosaic’s Discovery Platform, PRIME, will be presented Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information an

Vonage and ServiceNow Expand their Partnership24.3.2026 09:20:00 CET | Press release

Vonage Contact Center with ServiceNow Voice integrates enterprise-grade voice and AI capabilities directly into enterprise workflows, boosting agent productivity and customer engagement Vonage, part of Ericsson (NASDAQ: ERIC), today announced the launch of its native integration with ServiceNow Voice, built on the ServiceNow AI Platform, embedding enterprise-grade voice and real-time AI capabilities directly into ServiceNow Customer Service Management (CSM) and IT Service Management (ITSM) workflows for Vonage Contact Center (VCC) customers. Vonage provides a unified service environment for enterprise customer service and IT support teams, enabling agents to deliver exceptional customer experiences while driving improvements to service performance. The integration of VCC with ServiceNow embeds real-time voice and AI capabilities into enterprise workflows, giving them the tools their agents need to streamline case progression, automate workflows, and reduce manual effort. Through the Vo

Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 09:00:00 CET | Press release

Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe

Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri

AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release

From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye